Cipher Pharmaceuticals Inc (CPH) Trading Down 3.9% After Analyst Downgrade
Shares of Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) fell 3.9% during mid-day trading on Tuesday after TD Securities lowered their price target on the stock from C$6.50 to C$5.00. TD Securities currently has a hold rating on the stock. Cipher Pharmaceuticals traded as low as C$4.69 and last traded at C$4.46. 19,760 shares were traded during trading, an increase of 97% from the average session volume of 10,046 shares. The stock had previously closed at C$4.64.
Separately, Bloom Burton cut shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 14th.
TRADEMARK VIOLATION NOTICE: “Cipher Pharmaceuticals Inc (CPH) Trading Down 3.9% After Analyst Downgrade” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/cipher-pharmaceuticals-inc-cph-trading-down-3-9-after-analyst-downgrade/1685888.html.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.